TG Therapeutics Inc. has announced its preliminary financial results for 2025 and provided guidance for 2026. The company reported preliminary total global revenue of approximately $616 million for the full year 2025, with BRIUMVI U.S. net product revenue reaching about $594 million. For 2026, TG Therapeutics expects total global revenue to rise significantly to a range of $875-900 million, including BRIUMVI U.S. net product revenue of $825-850 million. The company also projects operating expenses, excluding non-cash compensation, to be around $350 million, with an additional $100 million allocated for subcutaneous BRIUMVI inventory build and secondary manufacturer start-up costs. This outlook reflects a substantial anticipated increase in both global and U.S. revenue for BRIUMVI compared to the prior year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TG Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9625056-en) on January 13, 2026, and is solely responsible for the information contained therein.